Quick Answer
Ernexa Therapeutics Inc. reported Earnings Per Share Diluted of $2.24 (loss) per share for the year ending 2025.
- Ernexa Therapeutics Inc. showed an increase of +95.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Ernexa Therapeutics Inc.'s Earnings Per Share Diluted has declined by 48.3%.
- Historical annual values: Fiscal year 2025: $2.24 (loss) per share | Fiscal year 2024: $48.96 (loss) per share | Fiscal year 2023: $4.08 (loss) per share | Fiscal year 2022: $8.06 (loss) per share | Fiscal year 2021: $56.61 (loss) per share | Fiscal year 2020: $1.51 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: